Investor Dashboard
Key financial KPIs at a glance — % against revenues in QuickBooks-statement style.
Revenue Mix · % of Top Line
Cost Structure · % of Operating Cost
Use of Funds · % of $4.0M Raise
Problem & Solution
Profitable chain of community pharmacies with telehealth integration · $5M Y5 EBITDA target
The Problem
GCC community pharmacy is dominated by 3 large chains operating cookie-cutter outlets and 4,000+ single-store independents lacking scale. Mid-market consumers want personalized care, telehealth integration, and same-day prescription fulfillment — none of which the current market structure delivers.
Our Solution
A regional pharmacy chain combining traditional retail dispensing with integrated telehealth consultation (in-store kiosks + app), chronic-care subscription programs, and a private-label SKU line at 22% higher margin. Each store is ~120 sqm with 4 FTEs and breaks even in month 8.
Market Opportunity
$18B GCC Pharmacy addressable today
GCC pharmacy retail growing 11% CAGR · telehealth-integrated segment growing 28% CAGR
Prescription dispensing (50% of revenue, ~22% gross margin), OTC and wellness (28%, ~38% margin), telehealth consultation fees (12%, ~65% margin), and chronic-care subscriptions (10%, ~55% margin). Average ticket ~$28, transactions per store per day ~95.
Financial Statements · % vs Revenue
QuickBooks-style readout — every line shown as percentage of its parent total.
Revenue Mix
| Revenue Stream | % of Revenue | Share |
|---|---|---|
| Prescription Dispensing | 50.0% | 50% |
| OTC & Wellness | 28.0% | 28% |
| Telehealth Consultations | 12.0% | 12% |
| Chronic-Care Subscriptions | 10.0% | 10% |
| Total Revenue | 100.0% | 100% |
Cost Structure
| Cost Line | % of Cost | Share |
|---|---|---|
| Cost of Goods (Drugs) | 55.0% | 55% |
| Store Staff | 14.0% | 14% |
| Rent & Utilities | 10.0% | 10% |
| Marketing & Loyalty | 6.0% | 6% |
| Telehealth Doctor Network | 8.0% | 8% |
| G&A | 7.0% | 7% |
| Total Operating Cost | 100.0% | 100% |
Use of Funds — $4.0M Raise
| Allocation | % of Raise | Share |
|---|---|---|
| 11 New Store Openings | 60.0% | 60% |
| Telehealth Platform Build-Out | 15.0% | 15% |
| Private-Label SKU Development | 12.0% | 12% |
| Pharmacy License & Compliance | 8.0% | 8% |
| Working Capital | 5.0% | 5% |
| Total Use of Funds | 100.0% | 100% |
Valuation, Capital Structure & Forward View
An investment is a bet on the forward plan, so a trailing snapshot isn't enough. These are derived from this report's own ask and projections — not external estimates.
Capital Structure & Funding
A blended equity + debt structure — this round layers a credit facility (loan / project / trade / inventory finance) on top of the equity cheque. That puts leverage, debt service and lender covenants into the capital structure: drawdown conditions and coverage ratios are first-order diligence items, not footnotes.
How to read these
Rule of 40 sums forward revenue growth and EBITDA margin — ≥40 is healthy; below it flags growth bought at the cost of profit. Capital efficiency is Year-5 revenue per dollar raised. Entry multiple divides the disclosed cap / pre-money / asking price by Year-3 revenue, shown only where disclosed (n/d = not derivable). Verify against primary diligence.
Traction & Proof Points
- 3 stores operational, 2 profitable, 1 ramping (month 5)
- $2.4M run-rate revenue · 18% blended gross margin · -8% EBITDA (still investing)
- Telehealth consultation attach rate 14% of footfall · 4.7★ Google reviews avg
Moat & Exit Strategy
Defensible Moat
Telehealth integration creates a recurring revenue layer (chronic-care subs at 92% annual retention) that single-store independents can't replicate. Private-label SKUs lift gross margin 7pp vs branded-only stores. Multi-store dataset improves SKU mix per location, lifting same-store sales 18% in year 2.
Exit Path
Strategic acquisition by a regional pharmacy major (Aster, Life Pharmacy, Bin Sina) or healthcare conglomerate at 8–12x EBITDA, or roll-up into a healthcare REIT structure for stabilized cash yield within 5–7 years.
Key Risks
- GCC pharmacy regulation requires per-store license — slow expansion ceiling
- Margin compression as large chains cut prices to defend share
- Telehealth regulation evolving across UAE / KSA jurisdictions
When the Thesis Breaks
Read this before trusting the forward numbers. The case rests on operating leverage — revenue growth converting into a holding-or-expanding EBITDA margin. The fastest way it breaks: a period where revenue grows but EBITDA falls (margin compression).
If any of the Key Risks above materialise, the forward projections in this report should be treated as suspended until the model is re-underwritten. The single most material trigger to watch: GCC pharmacy regulation requires per-store license — slow expansion ceiling.